This study has for the first time demonstrated high rates of prescribing drugs for psychosis with dosing recommendations based on CYP2D6 genotype in an EIP cohort, yet adoption of PGx testing to determine CYP2D6 genotype is to date limited. This evidence concerns the gene CYP2D6 and psychotic disorder.